Allopurinol benefits left ventricular mass and endothelial dysfunction in chronic kidney disease

Journal of the American Society of Nephrology

Volumn 22, Issue 7, 2011, Pages 1382-1389

  Kao, Michelle P ^a   Ang, Donald S ^a   Gandy, Stephen J ^a   Nadir, M Adnan ^a   Houston, J Graeme ^a   Lang, Chim C ^a   Struthers, Allan D ^a  

^a UNIVERSITY OF DUNDEE   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

ALLOPURINOL; PLACEBO;

ADULT; AGED; ARTERIAL STIFFNESS; ARTICLE; BRACHIAL ARTERY; CARDIOVASCULAR MAGNETIC RESONANCE; CHRONIC KIDNEY DISEASE; CONTROLLED STUDY; DOUBLE BLIND PROCEDURE; DRUG TOLERANCE; ENDOTHELIAL DYSFUNCTION; FEMALE; FLOW MEDIATED DILATION; HEART LEFT VENTRICLE HYPERTROPHY; HEART LEFT VENTRICLE MASS; HUMAN; MALE; MULTIPLE CYCLE TREATMENT; PRIORITY JOURNAL; PULSE WAVE; RANDOMIZED CONTROLLED TRIAL; TREATMENT OUTCOME; UNSPECIFIED SIDE EFFECT; VASODILATATION;

EID: 79960141065     PISSN: 10466673     EISSN: 15333450     Source Type: Journal    
DOI: 10.1681/ASN.2010111185     Document Type: Article

References (30)

1. Foley RN, Parfrey PS, Sarnak MJ: Clinical epidemiology of cardiovascular disease in chronic renal disease. Am J Kidney Dis 32[5 Suppl 3]: S112-S119, 1998 (Pubitemid 28527268)
2. Wanner C, Krane V, Marz W, Olschewski M, Mann JF, Ruf G, Ritz E: Atorvastatin in patients with type 2 diabetes mellitus undergoing hemodialysis. N Engl J Med 353: 238-248, 2005 (Pubitemid 41058323)
3. Fellstrom BC, Jardine AG, Schmieder RE, Holdaas H, Bannister K, Beutler J, Chae DW, Chevaile A, Cobbe SM, Gronhagen-Riska C, De Lima JJ, Lins R, Mayer G, McMahon AW, Parving HH, Remuzzi G, Samuelsson O, Sonkodi S, Sci D, Suleymanlar G, Tsakiris D, Tesar V, Todorov V, Wiecek A, Wuthrich RP, Gottlow M, Johnsson E, Zannad F: Rosuvastatin and cardiovascular events in patients undergoing hemodialysis. N Engl J Med 360: 1395-1407, 2009
4. Sharp Collaborative Group: Study of Heart and Renal Protection (SHARP): Randomized trial to assess the effects of lowering lowdensity lipoprotein cholesterol among 9,438 patients with chronic kidney disease. Am Heart J 160: 785-794.e710, 2010
5. Butler R, Morris AD, Belch JJ, Hill A, Struthers AD: Allopurinol normalizes endothelial dysfunction in type 2 diabetics with mild hypertension. Hypertension 35: 746-751, 2000 (Pubitemid 30165320)
6. Guthikonda S, Sinkey C, Barenz T, Haynes WG: Xanthine oxidase inhibition reverses endothelial dysfunction in heavy smokers. Circulation 107: 416-421, 2003 (Pubitemid 36158043)
7. Cardillo C, Kilcoyne CM, Cannon RO III, Quyyumi AA, Panza JA: Xanthine oxidase inhibition with oxypurinol improves endothelial vasodilator function in hypercholesterolemic but not in hypertensive patients. Hypertension 30: 57-63, 1997 (Pubitemid 27306347)
8. Foley RN, Parfrey PS, Harnett JD, Kent GM, Martin CJ, Murray DC, Barre PE: Clinical and echocardiographic disease in patients starting end-stage renal disease therapy. Kidney Int 47: 186-192, 1995
9. Paoletti E, Bellino D, Cassottana P, Rolla D, Cannella G: Left ventricular hypertrophy in nondiabetic predialysis CKD. Am J Kidney Dis 46: 320-327, 2005 (Pubitemid 41040362)
10. Levy D, Garrison RJ, Savage DD, Kannel WB, Castelli WP: Prognostic implications of echocardiographically determined left ventricular mass in the Framingham Heart Study. N Engl J Med 322: 1561-1566, 1990 (Pubitemid 20176696)
11. Koren MJ, Ulin RJ, Koren AT, Laragh JH, Devereux RB: Left ventricular mass change during treatment and outcome in patients with essential hypertension. Am J Hypertens 15: 1021-1028, 2002 (Pubitemid 35397534)
12. Verdecchia P, Schillaci G, Borgioni C, Ciucci A, Gattobigio R, Zampi I, Reboldi G, Porcellati C: Prognostic significance of serial changes in left ventricular mass in essential hypertension. Circulation 97: 48-54, 1998 (Pubitemid 28036154)
13. Laakso JT, Teravainen TL, Martelin E, Vaskonen T, Lapatto R: Renal xanthine oxidoreductase activity during development of hypertension in spontaneously hypertensive rats. J Hypertens 22: 1333-1340, 2004 (Pubitemid 38888079)
14. Xu X, Hu X, Lu Z, Zhang P, Zhao L, Wessale JL, Bache RJ, Chen Y: Xanthine oxidase inhibition with febuxostat attenuates systolic overload-induced left ventricular hypertrophy and dysfunction in mice. J Card Fail 14: 746-753, 2008
15. Silberberg JS, Barre PE, Prichard SS, Sniderman AD: Impact of left ventricular hypertrophy on survival in end-stage renal disease. Kidney Int 36: 286-290, 1989 (Pubitemid 19202488)
16. Wachtell K, Okin PM, Olsen MH, Dahlof B, Devereux RB, Ibsen H, Kjeldsen SE, Lindholm LH, Nieminen MS, Thygesen K: Regression of electrocardiographic left ventricular hypertrophy during antihypertensive therapy and reduction in sudden cardiac death: The LIFE Study. Circulation 116: 700-705, 2007 (Pubitemid 47260463)
17. Okin PM, Wachtell K, Devereux RB, Harris KE, Jern S, Kjeldsen SE, Julius S, Lindholm LH, Nieminen MS, Edelman JM, Hille DA, Dahlof B: Regression of electrocardiographic left ventricular hypertrophy and decreased incidence of new-onset atrial fibrillation in patients with hypertension. JAMA 296: 1242-1248, 2006 (Pubitemid 44394895)
18. Okin PM, Devereux RB, Harris KE, Jern S, Kjeldsen SE, Julius S, Edelman JM, Dahlof B: Regression of electrocardiographic left ventricular hypertrophy is associated with less hospitalization for heart failure in hypertensive patients. Ann Intern Med 147: 311-319, 2007 (Pubitemid 351664558)
19. Okin PM, Devereux RB, Jern S, Kjeldsen SE, Julius S, Nieminen MS, Snapinn S, Harris KE, Aurup P, Edelman JM, Wedel H, Lindholm LH, Dahlof B: Regression of electrocardiographic left ventricular hypertrophy during antihypertensive treatment and the prediction of major cardiovascular events. JAMA 292: 2343-2349, 2004 (Pubitemid 39491918)
20. Schillaci G, Pirro M, Mannarino E: Left ventricular hypertrophy reversal and prevention of diabetes: Two birds with one stone? Hypertension 50: 851-853, 2007
21. Stewart GA, Gansevoort RT, Mark PB, Rooney E, McDonagh TA, Dargie HJ, Stuart R, Rodger C, Jardine AG: Electrocardiographic abnormalities and uremic cardiomyopathy. Kidney Int 67: 217-226, 2005 (Pubitemid 40019243)
22. Simpson HJ, Gandy SJ, Houston JG, Rajendra NS, Davies JI, Struthers AD: Left ventricular hypertrophy: Reduction of blood pressure already in the normal range further regresses left ventricular mass. Heart 96: 148-152, 2009
23. Stewart GA, Foster J, Cowan M, Rooney E, McDonagh T, Dargie HJ, Rodger RS, Jardine AG: Echocardiography overestimates left ventricular mass in hemodialysis patients relative to magnetic resonance imaging. Kidney Int 56: 2248-2253, 1999 (Pubitemid 30004755)
24. George J, Carr E, Davies J, Belch JJ, Struthers A: High-dose allopurinol improves endothelial function by profoundly reducing vascular oxidative stress and not by lowering uric acid. Circulation 114: 2508-2516, 2006 (Pubitemid 44901524)
25. Struthers AD, Donnan PT, Lindsay P, McNaughton D, Broomhall J, MacDonald TM: Effect of allopurinol on mortality and hospitalisations in chronic heart failure: A retrospective cohort study. Heart 87: 229-234, 2002 (Pubitemid 34177675)
26. Wei L, Fahey T, Struthers AD, MacDonald TM: Association between allopurinol and mortality in heart failure patients: A long-term follow-up study. Int J Clin Pract 63: 1327-1333, 2009
27. Mark PB, Johnston N, Groenning BA, Foster JE, Blyth KG, Martin TN, Steedman T, Dargie HJ, Jardine AG: Redefinition of uremic cardiomyopathy by contrast-enhanced cardiac magnetic resonance imaging. Kidney Int 69: 1839-1845, 2006
28. London GM, Pannier B, Guerin AP, Blacher J, Marchais SJ, Darne B, Metivier F, Adda H, Safar ME: Alterations of left ventricular hypertrophy in and survival of patients receiving hemodialysis: Follow-up of an interventional study. J Am Soc Nephrol 12: 2759-2767, 2001 (Pubitemid 33115424)
29. Goicoechea M, de Vinuesa SG, Verdalles U, Ruiz-Caro C, Ampuero J, Rincon A, Arroyo D, Luno J: Effect of allopurinol in chronic kidney disease progression and cardiovascular risk. Clin J Am Soc Nephrol 5: 1388-1393, 2010
30. Corretti MC, Anderson TJ, Benjamin EJ, Celermajer D, Charbonneau F, Creager MA, Deanfield J, Drexler H, Gerhard-Herman M, Herrington D, Vallance P, Vita J, Vogel R: Guidelines for the ultrasound assessment of endothelial-dependent flow-mediated vasodilation of the brachial artery: A report of the International Brachial Artery Reactivity Task Force. J Am Coll Cardiol 39: 257-265, 2002 (Pubitemid 34084631)